Tamás Habon

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat

Eszter Szabados, GaborM Fischer, Kálmán Tóth et al. · Free Radical Biology and Medicine · 1999 · 140 citations

Cardiac Muscle, Cardiomyopathy, Heart Failure +11

In Vitro Antioxidant Properties of Pentoxifylline, Piracetam, and Vinpocetine

Beáta Horváth, Zsolt Márton, Róbert Halmosi et al. · Clinical Neuropharmacology · 2002 · 93 citations

Phenazine Methosulphate, Biochemistry, Vitro Antioxidant Properties +11

Glycoprotein IIIA Gene (<i>PIA</i>) Polymorphism and Aspirin Resistance: Is There Any Correlation?

Előd Papp, Viktória Havasi, Judit Bene et al. · Annals of Pharmacotherapy · 2005 · 62 citations

Prevention of Doxorubicin-Induced Acute Cardiotoxicity by an Experimental Antioxidant Compound

Péter Deres, Róbert Halmosi, Ambrus Tóth et al. · Journal of Cardiovascular Pharmacology · 2004 · 60 citations

Antioxidant H-2545, Heart Failure, Chemoprevention Strategy +17